All Outputs (14)

Biological function and clinical implication of coagulation proteins during malignant transformation of pancreatic cells (2023)
Thesis
Haque, F. Biological function and clinical implication of coagulation proteins during malignant transformation of pancreatic cells. (Thesis). Hull York Medical School. https://hull-repository.worktribe.com/output/4371279

The premalignant pancreatic cellular genotype can remain stable for years before rapid malignant transformation, often associated with inflammation. Tissue factor (TF) is an inflammatory modulator regulated by factor VIIa (fVIIa) for its levels and a... Read More about Biological function and clinical implication of coagulation proteins during malignant transformation of pancreatic cells.

Cancer patients’ experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study) (2022)
Journal Article
Benelhaj, N. E., Hutchinson, A., Maraveyas, A., & Johnson, M. (2022). Cancer patients’ experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study). PLoS ONE, 17(10), Article e0276754. https://doi.org/10.1371/journal.pone.0276754

Background: The diagnosis of symptomatic cancer-associated thrombosis often causes distress and alarm for patients, especially for those unaware of the risk, or the signs and symptoms to look out for. There are few data about cancer patients’ experie... Read More about Cancer patients’ experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study).

Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients (2022)
Journal Article
Ettelaie, C., Benelhaj, N., Featherby, S., Haque, F., Johnson, M., Cooke, J., & Maraveyas, A. (2022). Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients. Journal of Biotechnology and Biomedicine, 5(2), 78-93. https://doi.org/10.26502/jbb.2642-280050

Predicting which cancer patients are at risk of thrombosis remains a key challenge to effective thromboprophylaxis. This study was based on the hypothesis that the rapid release of TF-containing MV occurs in cancer cells that possess high levels of T... Read More about Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients.

Synthesis and analysis of small molecules to restrain the function of tissue factor within tumour cells (2021)
Journal Article
Adeniran, O. I., Mohammad, M. A., Featherby, S., Maraveyas, A., Boa, A. N., & Ettelaie, C. (2021). Synthesis and analysis of small molecules to restrain the function of tissue factor within tumour cells. Frontiers in Bioscience-Landmark, 26(10), 752-764. https://doi.org/10.52586/4985

Introduction: The restriction of prolyl-protein cis/trans isomerase 1 (Pin1) activity has been shown to prevent the release of tissue factor (TF) leading to the accumulation of the latter protein within the cell. This study tested the ability of nove... Read More about Synthesis and analysis of small molecules to restrain the function of tissue factor within tumour cells.

De-palmitoylation of tissue factor regulates its activity, phosphorylation and cellular functions (2021)
Journal Article
Ettelaie, C., Featherby, S., Rondon, A. M. R., Greenman, J., Versteeg, H. H., & Maraveyas, A. (2021). De-palmitoylation of tissue factor regulates its activity, phosphorylation and cellular functions. Cancers, 13(15), Article 3837. https://doi.org/10.3390/cancers13153837

In this study, the role of de-palmitoylation of tissue factor (TF) in the decryption of its activity was explored. TF-tGFP constructs were prepared by mutagenesis-substitution at Cys245 to prevent or mimic palmitolyation. Additionally, to reduce TF d... Read More about De-palmitoylation of tissue factor regulates its activity, phosphorylation and cellular functions.

Factor VIIa regulates the level of cell-surface tissue factor through separate but cooperative mechanisms (2021)
Journal Article
Madkhali, Y., Rondon, A. M., Featherby, S., Maraveyas, A., Greenman, J., & Ettelaie, C. (2021). Factor VIIa regulates the level of cell-surface tissue factor through separate but cooperative mechanisms. Cancers, 13(15), Article 3718. https://doi.org/10.3390/cancers13153718

Procoagulant activity of tissue factor (TF) in response to injury or inflammation is accompanied with cellular signals which determine the fate of cells. However, to prevent excessive signalling, TF is rapidly dissipated through release into microves... Read More about Factor VIIa regulates the level of cell-surface tissue factor through separate but cooperative mechanisms.

CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study (2018)
Journal Article
Jackson, G., Gabe, R., Johnson, M., Date, K., Harman, D., Maraveyas, A., Roy, R., & Lind, M. J. (2019). CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study. Journal of Geriatric Oncology, 10(1), 175-177. https://doi.org/10.1016/j.jgo.2018.07.005

One of the primary risk factors in the development of cancer is older age. The demographic shift to an ageing population has given rise to an increased number of older patients with cancer. The extreme heterogeneity within this population renders app... Read More about CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study.

Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy (2016)
Journal Article
Broughton, L. J., Giuntini, F., Savoie, H., Bryden, F., Boyle, R. W., Maraveyas, A., & Madden, L. A. (2016). Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy. Journal of photochemistry and photobiology. B, Biology, 163, 374-384. https://doi.org/10.1016/j.jphotobiol.2016.09.001

Duramycin, through binding with phosphatidylethanolamine (PE), has been shown to be a selective molecular probe for the targeting and imaging of cancer cells. Photodynamic therapy aims to bring about specific cytotoxic damage to tumours through deliv... Read More about Duramycin-porphyrin conjugates for targeting of tumour cells using photodynamic therapy.

Duramycin-induced calcium release in cancer cells (2016)
Journal Article
Broughton, L. J., Crow, C., Madden, L. A., & Maraveyas, A. (2016). Duramycin-induced calcium release in cancer cells. Anti-cancer drugs, 27(3), 173-182. https://doi.org/10.1097/cad.0000000000000313

Introduction: Duramycin through binding with phosphatidylethanolamine (PE) has shown potential to be an effective anti-tumour agent. However its mode of action in relation to tumour cells is not fully understood. Methods: PE expression on the surface... Read More about Duramycin-induced calcium release in cancer cells.

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients (2016)
Journal Article
Van der Hulle, T., den Exter, P. L., Planquette, B., Meyer, G., Soler, S., Monreal, M., …Klok, F. A. (2016). Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. Journal of thrombosis and haemostasis : JTH, 14(1), 105-113. https://doi.org/10.1111/jth.13172

Essentials: We performed a pooled analysis of 926 patients with cancer-associated incidental pulmonary embolism (IPE). Vitamin K antagonists (VKA) are associated with a higher risk of major hemorrhage. Recurrence risk is comparable after subsegmental... Read More about Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (2015)
Journal Article
Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., …Bridgewater, J. A. (2015). Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. The lancet oncology, 16(8), 967-978. https://doi.org/10.1016/S1470-2045%2815%2900139-4

© 2015 Valle et al. Open Access article distributed under the terms of CC BY. Background: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors... Read More about Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control (2014)
Journal Article
Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H. M., …Sebag-Montefiore, D. (2014). Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 25(7), 1356-1362. https://doi.org/10.1093/annonc/mdu147

Background: In stage III colon cancer, oxaliplatin/5-fluorouracil (5-FU)-based adjuvant chemotherapy (FOLFOX) improves disease-free survival (DFS) and overall survival (OS). In rectal adenocarcinoma following neoadjuvant chemoradiation (CRT), we exam... Read More about Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (2010)
Journal Article
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., …Bridgewater, J. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine, 362(14), 1273-1281. https://doi.org/10.1056/NEJMoa0908721

BACKGROUND:There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study involving 86 patients to compare cisplatin plus gemcitabine with gemcit... Read More about Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma (2009)
Journal Article
Weber, J., Thompson, J. A., Hamid, O., Berman, D., Amin, A., Ron, I., …O'Day, S. J. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5591-5598. https://doi.org/10.1158/1078-0432.CCR-09-1024

Purpose: Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylacti... Read More about A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.